Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis

Blood Cancer J. 2015 Oct 2;5(10):e356. doi: 10.1038/bcj.2015.78.

Authors

D Esteban¹, N Tovar¹, R Jiménez¹, R Santacruz¹, T Baumann¹, M C Pastor¹, A de la Riva¹, E Carrera¹, S Chaves¹, C Royo², A Navarro², S Rodríguez³, C Ayuso³, G Riu⁴, N Creus⁴, B Gómez⁴, E Giné¹, A López-Guillermo¹, J Delgado¹

Affiliations

¹ Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
² Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.
³ Department of Radiology, Hospital Clínic, Barcelona, Spain.
⁴ Department of Pharmacy, Hospital Clínic, Barcelona, Spain.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Case-Control Studies
Female
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / mortality
Patient Selection*
Retrospective Studies